Effect of Parasternal Plane Block on Intraoperative Nociception

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-7
SponsorDiskapi Yildirim Beyazit Education and Research Hospital

About this trial

Effective pain control during pediatric cardiac surgery remains a major clinical challenge, particularly in procedures involving median sternotomy, which is associated with intense nociceptive stimulation. Inadequate intraoperative analgesia may lead to increased opioid requirements, hemodynamic instability, delayed extubation, and prolonged intensive care unit stay. Objective monitoring of nociception may provide valuable information beyond conventional hemodynamic parameters in this vulnerable population.

This prospective randomized controlled study aims to evaluate the effect of ultrasound-guided parasternal plane block on intraoperative nociception in pediatric patients undergoing cardiac surgery with median sternotomy. Intraoperative nociception will be objectively assessed using the Pain Index Monitor (PAM), based on skin conductance measurements.

The results of this study are expected to provide objective evidence regarding the efficacy of parasternal plane block in attenuating nociceptive responses during pediatric cardiac surgery and to support the integration of regional anesthesia techniques and objective nociception monitoring into perioperative pain management strategies for children.

Eligibility criteria

Qualifiers

Age between 6 months and 7 years

Scheduled for elective congenital cardiac surgery

Planned median sternotomy

American Society of Anesthesiologists (ASA) physical status II-III

Disqualifiers

Emergency surgery or redo sternotomy

Age <6 months or >7 years

ASA physical status I or >III

Severe neurological disorders preventing reliable application of behavioral pain scales

Trial design

Treatments tested in this trial

  • Parasternal Plane Block
  • Group without peripheral nerve block

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators